Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application to the U.S. FDA requesting permission to manufacture and market a generic version of Truvada (emtricitabine and tenofovir disoproxil fumarate).
The details can be read here.
No comments:
Post a Comment